en
Scientific article
Open access
English

The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease

Published inBMC infectious diseases, vol. 17, no. 1, 45
Publication date2017
Abstract

There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens their life expectancy. The Named Patient Program in Europe included patients with advanced chronic hepatitis C, a life expectancy of less than 12 months and no other treatment options.

Citation (ISO format)
YOUNG, Jim et al. The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease. In: BMC infectious diseases, 2017, vol. 17, n° 1, p. 45. doi: 10.1186/s12879-016-2106-x
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
ISSN of the journal1471-2334
564views
333downloads

Technical informations

Creation03/09/2017 10:21:00 AM
First validation03/09/2017 10:21:00 AM
Update time03/15/2023 1:37:49 AM
Status update03/15/2023 1:37:48 AM
Last indexation01/16/2024 11:50:06 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack